Ibex Medical Analytics, a pioneer in AI-based cancer diagnostics, and KSM, the Research and Innovation Center of Maccabi Healthcare Services, Israel's leading HMO, has announced the deployment of Galen Gastric at Maccabi’s pathology institute.
Gastric cancer is among the most common malignant diseases worldwide, with over a million new cases each year. Pathologists play a crucial role in the detection and diagnosis of cancer, with their assessments being vital for reaching correct treatment decisions by oncologists, and improving patient survival rates. However, a rise in cancer prevalence and advances in personalised medicine have resulted in growing diagnostic complexity that significantly increases pathologists’ workloads. In recent years, as pathology laboratories transition towards digital solutions, pathologists can implement artificial intelligence (AI)-enhanced workflows to improve quality and efficiency of cancer diagnosis, resulting in better patient care.
Ibex transforms cancer diagnosis by harnessing Strong AI and Machine Learning technology at an unprecedented scale. Ibex's Galen platform helps pathologists improve the quality of cancer diagnosis, implement real-time quality control, reduce turnaround time and boost productivity, and has demonstrated outstanding accuracy and utility in clinical studies.
Galen Gastric is an integrated diagnostics and quality control solution that supports pathologists in the detection of gastric cancer, dysplasia, Helicobacter pylori and other important clinical findings. The solution is an addition to Galen Prostate and Galen Breast that have already been deployed at Maccabi Healthcare Services, as well as other laboratories worldwide, where they are used in everyday clinical practice. With this deployment, Maccabi becomes the only health system in the world to use AI for multi-tissue cancer detection on breast, prostate and gastric biopsies, supporting their pathologists with improved accuracy, quality control and efficiency.